SHORT REPORT

Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency

Fanny Mochel,1,2 Elodie Hainque,1,3 Domitille Gras,1,4 Isaac M Adanyeguh,1 Samantha Cailliet,5 Bénédicte Héron,6 Agathe Roubertie,7,8 Elsa Kaphan,9 Romain Valabregue,1,10 Daisy Rinaldi,1 Sandrine Vuillaumier,11 Raphael Schiffmann,12 Chris Ottolenghi,13,14 Jean-Yves Hogrel,15 Laurent Servais,16 Emmanuel Roze1,3

ABSTRACT

Objective  On the basis of our previous work with triheptanoin, which provides key substrates to the Krebs cycle in the brain, we wished to assess its therapeutic effect in patients with glucose transporter type 1 deficiency syndrome (GLUT1-DS) who objected to or did not tolerate ketogenic diets.

Methods  We performed an open-label pilot study with three phases of 2 months each (baseline, treatment, and withdrawal) in eight patients with GLUT1-DS (7–47 years old) with non-epileptic paroxysmal manifestations. We used a comprehensive patient diary to record motor and non-motor paroxysmal events. Functional 31P-NMR spectroscopy was performed to quantify phosphocreatine (PCr) and inorganic phosphate (Pi) within the occipital cortex during (activation) and after (recovery) a visual stimulus.

Results  Patients with GLUT1-DS experienced a mean of 30.8 (±27.7) paroxysmal manifestations (52% motor events) at baseline that dropped to 2.8 (±2.9, 76% motor events) during the treatment phase (p=0.028). After withdrawal, paroxysmal manifestations recurred with a mean of 24.2 (±21.9, 52% motor events; p=0.043). Furthermore, brain energy metabolism normalised with triheptanoin, that is, increased Pi/PCr ratio during brain activation compared to the recovery phase (p=0.021), and deteriorated when triheptanoin was withdrawn.

Conclusions  Treatment with triheptanoin resulted in a 90% clinical improvement in non-epileptic paroxysmal manifestations and a normalised brain bioenergetics profile in patients with GLUT1-DS.

Trial registration number  NCT02014883.

INTRODUCTION

Glucose transporter type 1 deficiency syndrome (GLUT1-DS) is caused by impaired glucose transport across the blood–brain barrier and into astrocytes, leading to cerebral energy deficiency.1 GLUT1-DS is caused by mutation in the SLC2A1 gene encoding the glucose transporter GLUT1. The phenotype typically comprises psychomotor retardation and permanent motor disorders, associated with paroxysmal manifestations including seizures and non-epileptic paroxysmal episodes.1,2 With age, seizures tend to become less prominent, whereas the frequency of non-epileptic paroxysmal episodes increases.4 In patients with milder forms of the disease, paroxysmal movement disorders, especially dyskinesia, may be the main or the sole manifestations of the disease and can occur at any age.3,4 Ketogenic diets, which provide ketone bodies to the brain and compensate for the lack of glucose, represent the standard of care in GLUT1-DS1,3 and are efficient on seizures control but less on movement disorders.2 Moreover, many patients, especially adolescents and adults, have difficulties in complying with the difficult constraints of these long-term diets and their side effects.

Triheptanoin is an odd-chain triglyceride with anaplerotic properties—that is, replenishing the pool of metabolic intermediates in the Krebs cycle. Unlike even-chain fatty acids metabolised to acetyl-CoA only, triheptanoin can indeed provide both acetyl-CoA and propionyl-CoA, two key carbon sources for the Krebs cycle. We showed that triheptanoin was able to produce C3-ketone bodies and restore energy metabolism and neurotransmission in pyruvate carboxylase (PC) deficiency, a severe metabolic disease that affects anaplerosis in the brain.6 Recently, we demonstrated that triheptanoin is able to correct bioenergetics in the brain of patients with Huntington’s disease (HD), a neurodegenerative disease associated with brain energy deficit.5 Here, we wished to obtain a proof-of-concept of the therapeutic effect of triheptanoin in patients with GLUT1-DS with non-epileptic paroxysmal manifestations for whom a ketogenic diet was not a therapeutic option.

SUBJECTS AND METHODS

Participants were enrolled in an interventional clinical protocol (NCT02014883) at the Pitié-Salpêtrière Hospital promoted by INSERM and approved by the local ethical committee. All participants and/or their legal guardians signed a written informed consent before participating in the study. Four children and four adults were enrolled with GLUT1-DS as defined by low cerebrospinal fluid to blood glucose ratio and a SLC2A1 missense mutation predicted to be pathogenic by prediction software programs. Patients had a chronic history of non-epileptic paroxysmal motor disorders, especially paroxysmal exercise-induced dyskinesia, non-kinesigenic dyskinesia, limb weakness, headache, drowsiness and dysphoria. Three patients also presented a mild cognitive deficit. All patients were on a normal diet prior to their enrolment as either they objected to or did not tolerate ketogenic diets. The
Movement disorders

study was divided into three phases of 2 months each (baseline, treatment and withdrawal). A trained dietician determined the patient’s caloric intake and adjusted their daily menus so that their diet remained isocaloric when triheptanoin was introduced. During the treatment phase, each patient was required to ingest 1 g/kg body-weight of triheptanoin per day, divided into 3–4 intakes during meals.

During each study phase, the patients and/or their legal guardians had to fill a comprehensive patient diary to record all motor (seizure, abnormal movement, body stiffness, body weakness, abnormal speech) and non-motor (headache, lethargy, mood swing) paroxysmal events (see online supplementary table e1). The approximate duration of each episode was recorded.

To assess the effect of triheptanoin on brain energy metabolism, functional 31P-NMR spectroscopy (f-MRS) was performed at 3 T at the end of each study phase in patients >15 years old (n=5). We targeted the visual cortex using a surface coil as it is easily stimulated and is close to the scalp, allowing an increased sensitivity to the surface coil. Furthermore, visual stimulation results in a large increase in glucose uptake and cerebral blood flow. Data were collected for 4 min at rest, 8 min during visual activation, 8 min after stimulation and analysed as described. The ratio of inorganic phosphate over phosphocreatine (Pi/PCr) was calculated to determine the brain response to cortical activation as it is directly related to the ADP levels which regulate mitochondrial oxidative metabolism.

Paired t tests were used for plasma analyses before and after treatment. For clinical parameters, Friedman tests were used to test the global hypothesis that all study phases were equal. If significant, Wilcoxon signed-rank tests were applied for pairwise phase comparisons with an α of 0.05. For the Pi/PCr ratio, repeated measures analysis of variance (ANOVA) were used to test the global hypothesis that all time points (rest, activation and recovery) were equal. If significant, paired t tests were applied for pairwise time comparisons with an α of 0.05.

Table 1 Main characteristics of patients with GLUT1-DS during the baseline, treatment and withdrawal phases

<table>
<thead>
<tr>
<th>Patients</th>
<th>P1</th>
<th>P2</th>
<th>P3</th>
<th>P4</th>
<th>P5</th>
<th>P6</th>
<th>Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>F</td>
<td>F</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>23</td>
<td>20</td>
<td>7</td>
<td>14</td>
<td>16</td>
<td>47</td>
<td>21.2</td>
</tr>
<tr>
<td>Total events</td>
<td>10</td>
<td>20</td>
<td>13</td>
<td>26</td>
<td>31</td>
<td>85</td>
<td>30.8</td>
</tr>
<tr>
<td>Motor events</td>
<td>6</td>
<td>16</td>
<td>10</td>
<td>1</td>
<td>12</td>
<td>54</td>
<td>16.5</td>
</tr>
<tr>
<td>6MWT (m)</td>
<td>502</td>
<td>558</td>
<td>458</td>
<td>514</td>
<td>471</td>
<td>504</td>
<td>501</td>
</tr>
<tr>
<td>9HPT(D/ND) (s)</td>
<td>17/18</td>
<td>18/23</td>
<td>19/21</td>
<td>15/17</td>
<td>18/22</td>
<td>14/16</td>
<td>17/19</td>
</tr>
<tr>
<td>Motor events</td>
<td>2</td>
<td>7</td>
<td>3</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>2.8</td>
</tr>
<tr>
<td>6MWT (m)</td>
<td>453</td>
<td>580</td>
<td>425</td>
<td>484</td>
<td>496</td>
<td>500</td>
<td>490</td>
</tr>
<tr>
<td>9HPT(D/ND) (s)</td>
<td>17/19</td>
<td>17/20</td>
<td>19/19</td>
<td>17/21</td>
<td>17/18</td>
<td>15/18</td>
<td>17/19</td>
</tr>
<tr>
<td>Motor events</td>
<td>9</td>
<td>9</td>
<td>1</td>
<td>1</td>
<td>15</td>
<td>40</td>
<td>12.5</td>
</tr>
<tr>
<td>6MWT (m)</td>
<td>532</td>
<td>528</td>
<td>461</td>
<td>496</td>
<td>475</td>
<td>510</td>
<td>500</td>
</tr>
<tr>
<td>9HPT(D/ND) (s)</td>
<td>15/22</td>
<td>14/20</td>
<td>17/17</td>
<td>17/17</td>
<td>18/20</td>
<td>15/15</td>
<td>16/19</td>
</tr>
</tbody>
</table>

Total events: all motor and non-motor paroxysmal manifestations during each 2-month-phase. Motor events: all motor paroxysmal episodes during each 2-month-phase. 6MWT: total distance walked (metres). 9HPT: the best score (seconds) obtained with the dominant hand. 9HPT: ND: best score (seconds) with the non-dominant hand. GLUT1-DS, glucose transporter type 1 deficiency syndrome; 6MWT, 6 min walk test; 9HPT, nine-hole pegboard test

RESULTS
Triheptanoin was well tolerated in all patients and none experienced gastrointestinal symptoms. Two patients were considered not compliant with the study as they consumed less than 50% of the recommended dose of triheptanoin and they (or their legal guardians) regularly omitted to fill the patient diary: a 13-year-old patient with mild cognitive delay who experienced only a few paroxysmal manifestations prior to the study, and a 23-year-old patient who was in denial of his disease. Owing to the small sample size, a per-protocol analysis was performed in the six patients who completed the study (see online supplementary table e2).

During the baseline phase, patients with GLUT1-DS experienced a mean of 30.8 (±27.7, 10–85) paroxysmal manifestations over 2 months, including 16.5 (±19.1, 1–54) motor episodes. When treated with triheptanoin for 2 months, paroxysmal manifestations dropped to a mean of 2.8 (±2.9, 0–7), including 2.2 (±2.6, 0–7) motor episodes (p=0.028, figure 1A), representing overall a 90% symptoms reduction. Two patients became free from paroxysmal manifestations (table 1). Although not significant, triheptanoin tended to also reduce the mean duration of the remaining motor episodes—59±44 min at baseline compared to 10±10 min with triheptanoin, p=0.224. On the patient-rated CGI-I scale, all patients reported a clear improvement when treated (‘much improved’). Conversely, during the 2-month withdrawal phase, patients experienced a mean of 24.2 (±21.9, 5–63) paroxysmal manifestations, including 12.5 (±14.5, 1–40) motor episodes (p=0.043, figure 1A). On the patient-rated CGI-I scale, five out of six patients reported a clear worsening during withdrawal (‘much worse’). The patients’ performance on the 6MWT and 9HPT was unchanged along the different phases of the study (table 1). On study completion, all patients wished to continue treatment with triheptanoin.

Compared to baseline, we observed a significant increase in plasma C3-carnitine (p=0.026) and C5-ketone bodies (p=0.008) on triheptanoin, reflecting its proper metabolism in the six compliant patients with GLUT1-DS. Conversely, the levels of triheptanoin metabolites were unchanged in the two non-compliant patients. During baseline, f-MRS showed an abnormal profile with no change in the Pi/PCr ratio during brain activation in patients with GLUT1-DS (figure 1B), unlike what we reported in healthy individuals.7 8 After 2 months on triheptanoin, the bioenergetics profile normalised and repeated measures ANOVA were significant for the Pi/PCr ratio (p=0.014). We observed an increase in the Pi/PCr ratio during visual stimulation and a decrease during recovery using paired t tests (p=0.021). The increased Pi/PCr ratio during brain activation reflected a proportional elevation of ADP, allowing increased mitochondrial ATP production with triheptanoin. After treatment withdrawal, the f-MRS profile returned to its preintervention abnormal state (figure 1B).

DISCUSSION
Treatment with triheptanoin promptly reduced the number of non-epileptic paroxysmal manifestations in children and adults with GLUT1-DS. This marked clinical response was associated with a significant production of C3-ketone bodies and the normalisation of the f-MRS bioenergetics profile during brain activation. Despite the absence of a control group, the magnitude of the intervention effect (90% reduction) combined with the metabolic responses argues against a placebo effect. The lack of change in effort-based outcome measures tests such as the 6MWT and 9HPT during treatment further argues against a generalised placebo effect in this study.

Our current observation in GLUT1-DS is supported by previous preclinical and clinical studies. In animal models of diseases associated with brain energy deficiency, triheptanoin improved energy metabolism and motor deficits.11–14 The first clinical response on neurological deficits with triheptanoin was reported in PC deficiency.15 Triheptanoin was also able to correct the bioenergetics profile in the brain of early affected patients with HD.1 Recently, a study in epileptic patients with GLUT1-DS showed a reduction in spike-waves on EEG about 90 min after taking antiepileptic drugs and triheptanoin.13 Despite the small sample size, our study provides strong evidence for a sustainable clinical improvement with triheptanoin in GLUT1-DS together with a robust metabolic response using a validated biomarker of brain energy metabolism. The confirmation of our data in a larger controlled study would hold promise for an alternative therapeutic approach in GLUT1-DS, especially for patients who cannot comply with the constraints of ketogenic diets.

Author affiliations
1Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France
2Department of Genetics, AP-HP, Pitié-Salpêtrière University Hospital, Paris, France
3Department of Neurology, AP-HP, Pitié-Salpêtrière University Hospital, Paris, France
4Department of Neuropediatrics, AP-HP, Robert Debré University Hospital, Paris, France
5Department of Dietetics, AP-HP, Pitié-Salpêtrière University Hospital, Paris, France
6Department of Neuropediatrics, AP-HP, Armand Trousseau University Hospital, Paris, France
7Department of Neuropediatrics, Gui de Chauclerc Hospital, Montpellier, France
8INSERM, U-1051, Institute of Neuroscience, Montpellier, France
9Department of Neurology, AP-HM, La Timone University Hospital, Marseille, France
10Center for Neuroimaging Research (CENIR), Institut du Cerveau et de la Moelle épinière, Paris, France
11Biochemistry and Genetic Laboratory, AP-HP, Bichat-Claude Bernard Hospital, Paris, France
12Baylor Research Institute, Institute of Metabolic Disease, Dallas, Texas, USA
13Metabolic Biochemistry Lab, AP-HP, Necker University Hospital, Paris, France
14University Paris Descartes, Paris, France
15Neuromuscular Physiology and Evaluation Lab, Institute of Myology, Paris, France
16Service of Clinical Research and Databases, Institute of Myology, Paris, France
17Institute of Neurology, Montpellier, France
18INSERM, U-1051, Institute of Neuroscience, Montpellier, France
19Department of Neurology, AP-HM, La Timone University Hospital, Marseille, France
20Center for Neuroimaging Research (CENIR), Institut du Cerveau et de la Moelle épinière, Paris, France
21Biochemistry and Genetic Laboratory, AP-HP, Bichat-Claude Bernard Hospital, Paris, France
22Baylor Research Institute, Institute of Metabolic Disease, Dallas, Texas, USA
23Metabolic Biochemistry Lab, AP-HP, Necker University Hospital, Paris, France
24University Paris Descartes, Paris, France
25Neuromuscular Physiology and Evaluation Lab, Institute of Myology, Paris, France
26Service of Clinical Research and Databases, Institute of Myology, Paris, France

Acknowledgements
Ultradynex Pharmaceutical Inc provided the investigational drug triheptanoin and funded the study. The research leading to these results has received funding from the programme ‘Investissements d’avenir’ ANR-10-IAIHU-06. The authors are grateful to Dr Isabelle An, Pr Jean-Christophe Corvol and Constance Flamand-Roze for their expertise on some of the material revised for this study, Dr Cécile Hubbsch for referral of a patient and Maxime Janin for excellent technical assistance.

Contributors FM was involved in the study concept and design, obtaining funding, study supervision and coordination, analysis and interpretation of data, statistical analysis and drafting/revising the manuscript. EH and DG were involved in the study coordination, acquisition of data, analysis and interpretation of data and drafting/revising the manuscript. IMA was involved in the acquisition of data, statistical analysis of data and drafting/revising the manuscript. SC was involved in the dietary management of the patient and analysis and interpretation of data. BH, AR and EK were involved in the referral of patients and drafting/revising the manuscript. RV, CO and J-YH were involved in the acquisition of data and drafting/revising the manuscript. DR and LS were involved in study supervision and coordination and acquisition of data, statistical analysis and drafting/revising the manuscript. LS was involved in the study concept and design and drafting/revising the manuscript. ER was involved in the study concept and design, analysis and interpretation of data, and drafting/revising the manuscript.

Funding ANR ‘Investissements d’avenir’ (grant no. ANR-10-IAIHU-06) and Ultradynex Pharmaceutical Inc.

Competing interests FM has a patent application regarding the use of triheptanoin in GLUT1-DS (WO2014093901) and received research support from Ultradynex and Jansen; travel funding from Genzyme; and honorarium on an advisory board from Ultradynex. EH received travel funding from Naturalia and Biologia. BH received honorarium as board membership from Biominar, grants and travel and meeting expenses funding from Actelion, travel and meeting expenses funding from...
Shire-HGT. RS has a patent application regarding the use of triheptanoin in GLUT1-DS (WO2014093901). RS received research support and honoraria from Genzyme Corporation, Shire and Amicus Therapeutics. JY-H received research funding from Roche and Valerion therapeutic. ER received research funding from Merz-Pharma, Orkyn, IP santé and Ultragreny; served on scientific advisory boards for Orkyn and Merz-pharma; received speech honorarium from Merz-pharma, Novartis, Ipsen-Pharma and Orkyn, received travel funding from Ipsen-Pharma, Teva, Abbvie and Merz-Pharma.

Patient consent Obtained.

Ethics approval Comité de Protection des Personnes, Ile-de-France VI (Paris 6).

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES


